Contingency ManagementNCT06931197
Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i
A study testing Contingency management in people with Contingency Management and Methamphetamine Use Disorder, run by Queen's Medical Center at 1 site in United States.
Trial summary
This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Contingency Management, Methamphetamine Use Disorder
- What is being tested?
- Contingency management
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2026to 13 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Admitted trauma patients
- Age greater than 18 years old
- Urine drug screen positive for methamphetamines during the current hospitalization
- Report at least weekly methamphetamine use
- First methamphetamine use greater than 6 months prior to injury
- Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
Show all 10Show fewer
- Glasgow Coma Scale ≥13 upon arrival to the emergency department
- Ability to understand and participate in study procedures
- Ability to communicate in English
- Expected discharge date within 45 days on the day of screening / recruitment
Who cannot join
- Active psychosis (reporting auditory or visual hallucinations)
- Under ongoing cardiorespiratory monitoring
- Evidence of moderate or severe traumatic brain injury
- Patients who are known to be pregnant
- Prisoners
- Individuals incarcerated at the time of their hospitalization
- Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i (2025-2026)
This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients.
The goals are:
Read more
- Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury
- To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.
- To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants.
- To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital.
For total of 12 weeks, participants will:
- Be visited on Mondays/Thursdays or Tuesdays/Fridays by the research team to complete urine analysis during the hospitalization
- Visit a follow up clinic up to 2 times per week on Mondays/Thursdays or Tuesdays/Fridays to complete urinalysis following discharge from the hospital
- Complete Treatment Effectiveness Assessments at 6 and 12 weeks
- Engage in qualitative interview at the end of the CM program
- Being tested
- Contingency management
- Keywords
- Contingency management, Methamphetamine Use Disorder, Contingency management during acute hospitalization, Contingency management in Trauma Injured Patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Contingency managementBehavioural
If the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. "great job!"). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic tablet, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date.
| Study group | Role | What they receive |
|---|---|---|
| Contingency management intervention | Experimental | Intervention is total of 12 weeks. During the hospitalization, participants will be visited by study personnel and will be asked to complete a urine drug screen that will screen for presence of methamphetamine on Mondays/Thursdays or Tuesdays/Fridays (M/Th or T/F). Once discharged, participants will be asked to come into the out patient clinic 2 times per week (M/Th or T/F) to complete a urine drug screen that will screen for presence of methamphetamine. If the specimen is negative for methamphetamine, the participants will be rewarded. Participants will also be asked to complete the Treatment Effectiveness Assessment (TEA) with study personnel. Receives: Behavioral: Contingency management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment
TEA (Treatment Effectiveness Assessment) at 6- and 12-weeks post-enrollment to assess both patient-reported medium-term program effectiveness. TEA asks individuals to respond to changes in four domains following a drug treatment program: Substance use, health, lifestyle, and community. The score for each domain can range from 1 (no change or not much) to 10 (much better), for total score of 4-40. This score allows for the prioritization of each participants values, and therefore does not require strict abstinence to demonstrate benefit from drug treatment.
Measured: From enrollment to 6 and 12 weeks
Secondary outcomes (1)
Conduct qualitative interviews with participants post-program
Interviews will be conducted as semi-structured qualitative interviews with participants post-program and will be transcribed and analyzed using a Template Analysis approach. Coders will conduct coding of the interview data to ultimately identify themes that will be used as the basis for interpretation. The final analysis of the qualitative data will include contrasts and comparisons made across interviews to examine overlaps and divergences across any relevant sub-samples (i.e. sex, age). Results will present thematic patterns, how frequently each code occurs, and any contradictory evidence. This will allow for the identification of common themes and perspectives, which will provide necessary cultural insights and possible adaptations for further implementation efforts.
Measured: At the end of the treatment at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2025
- Study start1 Apr 2026
- Primary completion13 Sep 2026
- Study completion13 Sep 2026
Why it stopped: The study never commenced. The funding went through as year 2 for NCT06532370
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Contingency ManagementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Participants will be assigned to the CM intervention group and for the total of 12 weeks, he/she will be followed up two times a week during the hospitalization and up to three times per week as an outpatient to engage in intervention.
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queen's Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06931197
- Sponsor's protocol ID
- RA-2025-012
- Status last verified
- Sep 2026
- First submitted
- 1 Apr 2025
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i (2025-2026)
- ClinicalTrials.gov ID
- NCT06931197
- Acronym / sponsor ID
- RA-2025-012
- Keywords
- Contingency management, Methamphetamine Use Disorder, Contingency management during acute hospitalization, Contingency management in Trauma Injured Patients
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: The study never commenced. The funding went through as year 2 for NCT06532370
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Queen's Medical CenterUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 13 Sep 2026 (actual)
- Study completion
- 13 Sep 2026 (actual)
- First posted
- 17 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients.
The goals are:
- Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury
- To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.
- To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants.
- To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital.
For total of 12 weeks, participants will:
- Be visited on Mondays/Thursdays or Tuesdays/Fridays by the research team to complete urine analysis during the hospitalization
- Visit a follow up clinic up to 2 times per week on Mondays/Thursdays or Tuesdays/Fridays to complete urinalysis following discharge from the hospital
- Complete Treatment Effectiveness Assessments at 6 and 12 weeks
- Engage in qualitative interview at the end of the CM program
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Participants will be assigned to the CM intervention group and for the total of 12 weeks, he/she will be followed up two times a week during the hospitalization and up to three times per week as an outpatient to engage in intervention.
| Arm | Type | Receives |
|---|---|---|
| Contingency management intervention | Experimental | Behavioral: Contingency managementIntervention is total of 12 weeks. During the hospitalization, participants will be visited by study personnel and will be asked to complete a urine drug screen that will screen for presence of methamphetamine on Mondays/Thursdays or Tuesdays/Fridays (M/Th or T/F). Once discharged, participants will be asked to come into the out patient clinic 2 times per week (M/Th or T/F) to complete a urine drug screen that will screen for presence of methamphetamine. If the specimen is negative for methamphetamine, the participants will be rewarded. Participants will also be asked to complete the Treatment Effectiveness Assessment (TEA) with study personnel. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Admitted trauma patients
- Age greater than 18 years old
- Urine drug screen positive for methamphetamines during the current hospitalization
- Report at least weekly methamphetamine use
- First methamphetamine use greater than 6 months prior to injury
Key exclusion criteria (7 listed)
- Active psychosis (reporting auditory or visual hallucinations)
- Under ongoing cardiorespiratory monitoring
- Evidence of moderate or severe traumatic brain injury
- Patients who are known to be pregnant
- Prisoners
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Contingency managementIf the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. "great job!"). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic tablet, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date. | Behavioural | Contingency management intervention |
Primary outcome
Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment
Time frame: From enrollment to 6 and 12 weeks
TEA (Treatment Effectiveness Assessment) at 6- and 12-weeks post-enrollment to assess both patient-reported medium-term program effectiveness. TEA asks individuals to respond to changes in four domains following a drug treatment program: Substance use, health, lifestyle, and community. The score for each domain can range from 1 (no change or not much) to 10 (much better), for total score of 4-40. This score allows for the prioritization of each participants values, and therefore does not require strict abstinence to demonstrate benefit from drug treatment.
1 secondary outcome
Conduct qualitative interviews with participants post-program
Time frame: At the end of the treatment at 12 weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Contingency Management
Not yet recruiting
Contingency Management to Promote Smoking Cessation Study
Smoking Cessation
Not yet recruiting
Supporting Health and Empowerment Through Contingency Management and Affect Regulation
HIV Risk
Recruiting
Maternal Outcomes: Mood, Alcohol Use, and Depressive Symptoms
Postpartum Depression (PPD), Alcohol Use
Recruiting
Smoking Cessation CM for Veterans With or at Risk for Cancer
Tobacco Use Disorder, Substance Use Disorder
Recruiting
Case Management Dyad
HIV, Pre-exposure Prophylaxis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Contingency management in people with Contingency Management and Methamphetamine Use Disorder, run by Queen's Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment (time frame: From enrollment to 6 and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.